Listen
REMODULIN
-
Opinions on drugs -
Posted on
Jan 05 2011
- Updated on
Feb 10 2011
Reason for request
Reassessment of actual benefit and improvement in actual benefit under article R-163-21 of the Social Security Code.
-
Clinical Benefit
| Moderate |
The actual benefit is moderate. |
Clinical Added Value
| minor |
The Transparency Committee is of the opinion that the REMODULIN range of proprietary drugs provides a minor improvement in actual benefit (IAB IV) in the treatment of idiopathic pulmonary arterial hypertension for patients in functional class III. |
Documents
Contact Us
Évaluation des médicaments
